Maitake Products - Mushroom Wisdom Breast Mate from Meshima - 120 Tablets
Meshima (Phellinus linteus), literally meaning "Women's Island", is a mushroom that grows on mulberry trees on an island with the same name located southwest of Japan. In 1968, prominent Japanese mycologists screened over 20 medicinal mushrooms and found Meshima to be the most potent. Now, 40 years later, U.S. researchers confirmed it in their studies which are particularly related to women's health.
Breast-Mate is designed to target nutritional support for specific body tissues. It is based on Meshima PL-fraction, the actual extract used in the U.S. studies, combined with other established ingredients, such as Maitake SX-fraction, Broccoli extract, Green Tea extract, Vitamin D3 and Folic Acid.
Clinically Tested, with a wide array of benefits:
- One of nature's most effective immune health boosters
- Quenches inflammatory reaction
- Specifically targets, supports adn defends healthy breast tissue
- Promising adjunct therapy shown to enhance some conventional treatments
About Mushroom Wisdom:
Mushroom Wisdom, Inc. (MWI) is a pioneer and leader of the highest quality dietary supplements derived from medicinal mushrooms. MWI was first created to introduce wonderful health benefits of Maitake mushroom (Grifola frondosa) to American people back in 1991. Since then MWI has been devoted to protect and promote health and well-being of the people by studying, developing, manufacturing, and marketing the highest quality nutritional supplements derived from medicinal mushrooms. Now MWI's products are available in more than 30 countries worldwide.
Mushroom Wisdom, Inc.(MWI) understands the critical significance of scientific studies to ensure the credibility and best use of its products. MWI puts a high priority on these studies, and has supported many of them conducted by various research institutes in Japan as well as in the US. These institutes include Shizuoka University, Showa University and Saga University in Japan, and National Cancer Institutes, Georgetown University, Cancer Treatment Centers of America and New York Medical College in the US.
Also, it should be noted that MWI has received the IND (Investigational New Drug) approval from the FDA for its Grifron-Pro Maitake D-Fraction (Tincture) for Phase II clinical studies on advanced breast and prostate cancer patients. It is very exceptional for a dietary supplement company to be successful in obtaining an IND approval for a dietary supplement product, since this has traditionally been regarded as a process by which giant pharmaceutical companies develop new drugs. However, it serves as a sign of the excellent quality of this product and the high standards of MWI.